Merck and Eisai team up in oncology; Is biotech in a bubble?;

@FierceBiotech: EuroBiotech: Billionaires plot Stallergenes merger, Cerenis set for IPO, Big Pharma-backed Opsona eyes IPO. Report | Follow @FierceBiotech

@JohnCFierce: You know Richard Gonzalez is sweating it out when he gives an interview like this ($ABBV). More from Reuters | Follow @JohnCFierce

@DamianFierce: "In 2009, $PCYC's shares fell to a record low 57 cents. $ABBV is paying cash and stock worth $261.25 a share." WSJ story | Follow @DamianFierce

> Merck ($MRK) and Eisai are teaming up on cancer R&D, planning studies that combine the former's PD-1 inhibitor Keytruda with two of the latter's oncology drugs. More

> Is biotech booming or just in a bubble? Bloomberg takes the temperature of investors and executives in the industry. Story

> Isis Pharmaceuticals ($ISIS) pocketed a $9 million milestone payment as part of its ongoing collaboration with Biogen Idec ($BIIB) in spinal muscular atrophy. News

Medical Device News

@FierceMedDev: Navidea joins forces with Norgine to market cancer imaging Dx in EU. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Now with ""s from OptiNose: Evidence that inhaled oxytocin improves social behavior among autistic patients spurs R&D. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: New superbug outbreak tied to endoscope devices surfaces amid FDA scrutiny. Article | Follow @EmilyWFierce

> EndoChoice raises $57M led by Deerfield to offer a better endoscopy view. News

> J&J ordered to hand over $5.6M in vaginal mesh trial. More

Pharma News

@FiercePharma: Health Canada pledges more plant inspections and more transparency. More from FiercePharmaManufacturing | Follow @FiercePharma

@EricPFierce: MS Pharma in Jordan gets $30M development loan to expand its drug manufacturing. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Novartis gets bragging rights on first U.S. biosim. But will its Neupogen copy sell? Story | Follow @CarlyHFierce

> Looking at an IPO? Watch shares soar at Novo Nordisk's newly public IT unit. News

> BMS, Pfizer's Eliquis gets a NICE boost in rivalry with Pradaxa, Xarelto. Article

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.